Literature DB >> 27048647

Mice with an NaV1.4 sodium channel null allele have latent myasthenia, without susceptibility to periodic paralysis.

Fenfen Wu1, Wentao Mi2, Yu Fu2, Arie Struyk3, Stephen C Cannon4.   

Abstract

Over 60 mutations of SCN4A encoding the NaV1.4 sodium channel of skeletal muscle have been identified in patients with myotonia, periodic paralysis, myasthenia, or congenital myopathy. Most mutations are missense with gain-of-function defects that cause susceptibility to myotonia or periodic paralysis. Loss-of-function from enhanced inactivation or null alleles is rare and has been associated with myasthenia and congenital myopathy, while a mix of loss and gain of function changes has an uncertain relation to hypokalaemic periodic paralysis. To better define the functional consequences for a loss-of-function, we generated NaV1.4 null mice by deletion of exon 12. Heterozygous null mice have latent myasthenia and a right shift of the force-stimulus relation, without evidence of periodic paralysis. Sodium current density was half that of wild-type muscle and no compensation by retained expression of the foetal NaV1.5 isoform was detected. Mice null for NaV1.4 did not survive beyond the second postnatal day. This mouse model shows remarkable preservation of muscle function and viability for haploinsufficiency of NaV1.4, as has been reported in humans, with a propensity for pseudo-myasthenia caused by a marginal Na(+) current density to support sustained high-frequency action potentials in muscle.
© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  SCN4A; channelopathy; congenital myasthenic syndrome; skeletal muscle; weakness

Mesh:

Substances:

Year:  2016        PMID: 27048647      PMCID: PMC4892753          DOI: 10.1093/brain/aww070

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  42 in total

1.  A sodium channel knockin mutant (NaV1.4-R669H) mouse model of hypokalemic periodic paralysis.

Authors:  Fenfen Wu; Wentao Mi; Dennis K Burns; Yu Fu; Hillery F Gray; Arie F Struyk; Stephen C Cannon
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

2.  Enhanced inactivation and pH sensitivity of Na(+) channel mutations causing hypokalaemic periodic paralysis type II.

Authors:  Alexey Kuzmenkin; Vanesa Muncan; Karin Jurkat-Rott; Chao Hang; Holger Lerche; Frank Lehmann-Horn; Nenad Mitrovic
Journal:  Brain       Date:  2002-04       Impact factor: 13.501

3.  Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy.

Authors:  Frank H Yu; Massimo Mantegazza; Ruth E Westenbroek; Carol A Robbins; Franck Kalume; Kimberly A Burton; William J Spain; G Stanley McKnight; Todd Scheuer; William A Catterall
Journal:  Nat Neurosci       Date:  2006-08-20       Impact factor: 24.884

4.  Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current.

Authors:  K Jurkat-Rott; N Mitrovic; C Hang; A Kouzmekine; P Iaizzo; J Herzog; H Lerche; S Nicole; J Vale-Santos; D Chauveau; B Fontaine; F Lehmann-Horn
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

5.  Gating pore current in an inherited ion channelopathy.

Authors:  Stanislav Sokolov; Todd Scheuer; William A Catterall
Journal:  Nature       Date:  2007-03-01       Impact factor: 49.962

Review 6.  Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis?

Authors:  E Matthews; M G Hanna
Journal:  J Physiol       Date:  2010-02-01       Impact factor: 5.182

7.  Aberrant patterning of neuromuscular synapses in choline acetyltransferase-deficient mice.

Authors:  Eugene P Brandon; Weichun Lin; Kevin A D'Amour; Donald P Pizzo; Bertha Dominguez; Yoshie Sugiura; Silke Thode; Chien-Ping Ko; Leon J Thal; Fred H Gage; Kuo-Fen Lee
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

8.  Targeted mutation of mouse skeletal muscle sodium channel produces myotonia and potassium-sensitive weakness.

Authors:  Lawrence J Hayward; Joanna S Kim; Ming-Yang Lee; Hongru Zhou; Ji W Kim; Kumudini Misra; Mohammad Salajegheh; Fen-fen Wu; Chie Matsuda; Valerie Reid; Didier Cros; Eric P Hoffman; Jean-Marc Renaud; Stephen C Cannon; Robert H Brown
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

9.  Mutation of a new sodium channel gene, Scn8a, in the mouse mutant 'motor endplate disease'.

Authors:  D L Burgess; D C Kohrman; J Galt; N W Plummer; J M Jones; B Spear; M H Meisler
Journal:  Nat Genet       Date:  1995-08       Impact factor: 38.330

10.  Do hyperpolarization-induced proton currents contribute to the pathogenesis of hypokalemic periodic paralysis, a voltage sensor channelopathy?

Authors:  Karin Jurkat-Rott; Frank Lehmann-Horn
Journal:  J Gen Physiol       Date:  2007-07       Impact factor: 4.086

View more
  10 in total

Review 1.  Sodium Channelopathies of Skeletal Muscle.

Authors:  Stephen C Cannon
Journal:  Handb Exp Pharmacol       Date:  2018

2.  Homozygous C-terminal loss-of-function NaV1.4 variant in a patient with congenital myasthenic syndrome.

Authors:  Andoni Echaniz-Laguna; Valérie Biancalana; Aleksandra Nadaj-Pakleza; Emmanuel Fournier; Emma Matthews; Michael G Hanna; Roope Männikkö
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-06-02       Impact factor: 10.154

3.  Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

Authors:  Jean-François Desaphy; Concetta Altamura; Savine Vicart; Bertrand Fontaine
Journal:  J Neuromuscul Dis       Date:  2021

4.  Hypokalaemic periodic paralysis and myotonia in a patient with homozygous mutation p.R1451L in NaV1.4.

Authors:  Sushan Luo; Marisol Sampedro Castañeda; Emma Matthews; Richa Sud; Michael G Hanna; Jian Sun; Jie Song; Jiahong Lu; Kai Qiao; Chongbo Zhao; Roope Männikkö
Journal:  Sci Rep       Date:  2018-06-26       Impact factor: 4.379

5.  A204E mutation in Nav1.4 DIS3 exerts gain- and loss-of-function effects that lead to periodic paralysis combining hyper- with hypo-kalaemic signs.

Authors:  Yosuke Kokunai; Carine Dalle; Savine Vicart; Damien Sternberg; Valérie Pouliot; Said Bendahhou; Emmanuel Fournier; Mohamed Chahine; Bertrand Fontaine; Sophie Nicole
Journal:  Sci Rep       Date:  2018-11-12       Impact factor: 4.379

6.  Myasthenic congenital myopathy from recessive mutations at a single residue in NaV1.4.

Authors:  Nathaniel Elia; Johanna Palmio; Marisol Sampedro Castañeda; Perry B Shieh; Marbella Quinonez; Tiina Suominen; Michael G Hanna; Roope Männikkö; Bjarne Udd; Stephen C Cannon
Journal:  Neurology       Date:  2019-03-01       Impact factor: 11.800

7.  Case report: Novel SCN4A variant associated with a severe congenital myasthenic syndrome/myopathy phenotype.

Authors:  Veronika M Berghold; Mahmoud Koko; Riccardo Berutti; Barbara Plecko
Journal:  Front Pediatr       Date:  2022-08-26       Impact factor: 3.569

8.  Dysfunction of NaV1.4, a skeletal muscle voltage-gated sodium channel, in sudden infant death syndrome: a case-control study.

Authors:  Roope Männikkö; Leonie Wong; David J Tester; Michael G Thor; Richa Sud; Dimitri M Kullmann; Mary G Sweeney; Costin Leu; Sanjay M Sisodiya; David R FitzPatrick; Margaret J Evans; Iona J M Jeffrey; Jacob Tfelt-Hansen; Marta C Cohen; Peter J Fleming; Amie Jaye; Michael A Simpson; Michael J Ackerman; Michael G Hanna; Elijah R Behr; Emma Matthews
Journal:  Lancet       Date:  2018-04-05       Impact factor: 79.321

9.  Substitutions of the S4DIV R2 residue (R1451) in NaV1.4 lead to complex forms of paramyotonia congenita and periodic paralyses.

Authors:  Hugo Poulin; Pascal Gosselin-Badaroudine; Savine Vicart; Karima Habbout; Damien Sternberg; Serena Giuliano; Bertrand Fontaine; Saïd Bendahhou; Sophie Nicole; Mohamed Chahine
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

10.  β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.

Authors:  An E Vanhaesebrouck; Richard Webster; Susan Maxwell; Pedro M Rodriguez Cruz; Judith Cossins; James Wickens; Wei-Wei Liu; Hakan Cetin; Jonathan Cheung; Hayley Ramjattan; Jacqueline Palace; David Beeson
Journal:  Brain       Date:  2019-12-01       Impact factor: 13.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.